181 related articles for article (PubMed ID: 30792047)
1. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases.
Ruzzenente A; Bagante F; Ratti F; Beal EW; Alexandrescu S; Merath K; Makris EA; Poultsides GA; Margonis GA; Weiss MJ; Popescu I; Aldrighetti L; Guglielmi A; Pawlik TM
HPB (Oxford); 2019 Sep; 21(9):1230-1239. PubMed ID: 30792047
[TBL] [Abstract][Full Text] [Related]
2. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
[TBL] [Abstract][Full Text] [Related]
3. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
[TBL] [Abstract][Full Text] [Related]
4. The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
Sasaki K; Morioka D; Conci S; Margonis GA; Sawada Y; Ruzzenente A; Kumamoto T; Iacono C; Andreatos N; Guglielmi A; Endo I; Pawlik TM
Ann Surg; 2018 Jan; 267(1):132-141. PubMed ID: 27763897
[TBL] [Abstract][Full Text] [Related]
5. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases.
Liao L; Sun H; He J; Liu Y; Pan Z; Wu X; Fan W; Peng J; Li C
BMC Surg; 2023 Sep; 23(1):271. PubMed ID: 37689651
[TBL] [Abstract][Full Text] [Related]
7. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
[TBL] [Abstract][Full Text] [Related]
8. Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.
Oshi M; Margonis GA; Sawada Y; Andreatos N; He J; Kumamoto T; Morioka D; Wolfgang CL; Tanaka K; Weiss MJ; Endo I
Ann Surg Oncol; 2019 Feb; 26(2):593-603. PubMed ID: 30483976
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
10. Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: A retrospective cohort study.
Mao R; Zhao JJ; Bi XY; Zhang YF; Li ZY; Zhou JG; Zhao H; Cai JQ
Int J Surg; 2018 May; 53():371-377. PubMed ID: 29229309
[TBL] [Abstract][Full Text] [Related]
11. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
[TBL] [Abstract][Full Text] [Related]
12. Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
Takeda Y; Mise Y; Takahashi Y; Ito H; Inoue Y; Yoshioka R; Ono Y; Saiura A
Ann Surg Oncol; 2022 Apr; 29(4):2383-2391. PubMed ID: 34851437
[TBL] [Abstract][Full Text] [Related]
13. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
14. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
[TBL] [Abstract][Full Text] [Related]
15. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
17. The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases.
Endo Y; Rueda BO; Woldesenbet S; Munir MM; Lima HA; Katayama ES; Shaikh CF; Guglielmi A; Ruzzenente A; Aldrighetti L; Alexandrescu S; Kitago M; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Surg Oncol; 2023 Sep; 128(4):560-568. PubMed ID: 37195231
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.
Goffredo P; Utria AF; Beck AC; Chun YS; Howe JR; Weigel RJ; Vauthey JN; Hassan I
J Gastrointest Surg; 2019 Oct; 23(10):1957-1963. PubMed ID: 30276588
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
[TBL] [Abstract][Full Text] [Related]
20. Predictive Factors for the Survival Outcomes of Preoperative Chemotherapy in Patients with Resectable and Borderline Resectable Colorectal Cancer with Liver Metastasis.
Inworn N; Senavat P; Aleenajitpong N; Chingchaimaneesri M; Siripoon T; Srirattanapong S; Suragul W; Ngamphaiboon N
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3037-3047. PubMed ID: 37774055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
